Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Checkpoint Inhibitor Therapy | Other | Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biopsy | Procedure | Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Gene Alterations in at-Progression Biopsy of Patricipants with Acquired Immune Escape | Number of Gene Alterations Will Be Evaluated Using NGS Approaches by Comparing At-Progression Biopsy with Pre-Treatment Biopsy | Day 1 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCSF Comp Canc Ctr | San Francisco | California | 94115 | United States | ||
| Dana-Farber Cancer Institute |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Boston |
| Massachusetts |
| 02215 |
| United States |
| Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology | St Louis | Missouri | 63108 | United States |
| Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion | New York | New York | 10032 | United States |
| Sarah Cannon Cancer Center | Arrington | Tennessee | 37014 | United States |
| Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O) | Toulouse | 31059 | France |
| Seoul National University Hospital; Department of Oncology | Seoul | 110-744 | South Korea |
| Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology | Seoul | 138-736 | South Korea |
| Clinica Universitaria de Navarra; Servicio de oncología | Pamplona | Navarre | 31008 | Spain |
| Hospital Univ Vall d'Hebron; Servicio de Oncologia | Barcelona | 08035 | Spain |
| Barts Hospital; Institute of Cancer | London | EC1M 6BQ | United Kingdom |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D009362 | Neoplasm Metastasis |
| ID | Term |
|---|---|
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D001706 | Biopsy |
| ID | Term |
|---|---|
| D003581 | Cytodiagnosis |
| D003584 | Cytological Techniques |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D013048 | Specimen Handling |
| D003949 | Diagnostic Techniques, Surgical |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
Not provided
Not provided